Predictive Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
AGPU$7.64+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Net Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue | $1,780,093 | $1,505,459 |
| Cost of sales | 634,796 | 505,107 |
| Gross profit | 1,145,297 | 1,000,352 |
| Operating expenses: | ||
| General and administrative expense | 9,428,496 | 11,110,735 |
| Operations expense | 4,127,268 | 3,798,425 |
| Sales and marketing expense | 1,510,861 | 1,358,907 |
| Loss on impairment of goodwill | - | 7,231,093 |
| Loss on impairment of finite-lived intangible assets | - | 3,349,375 |
| Loss on impairment of property and equipment | 162,905 | 185,469 |
| Total operating expenses | 15,229,530 | 27,034,004 |
| Total operating loss | (14,084,233) | (26,033,652) |
| Other income | 152,776 | 185,646 |
| Other expense | (64,967) | (5,275) |
| Gain on derivative instruments | 12,457 | 115,647 |
| Net loss | $(13,983,967) | $(25,737,634) |
| Net loss per common share – basic and diluted | $(3.48) | $(6.98) |
| Weighted average shares used in computation – basic and diluted | 4,014,848 | 3,685,954 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.